Institute of Pathological Physiology, School of Medicine, Comenius University, Sasinkova 4, Bratislava, Slovakia.
Neoplasma. 2011;58(1):1-8. doi: 10.4149/neo_2011_01_1.
Hematopoietic stem cell transplantation (HSCT) offers patients with malignant and nonmalignant diseases the oportunity to pursue life-prolonging therapy. The number of survivors after successful HSCT is continually increasing. However, HSCT can induce tissue and organ damage that occurs not only "on treatment" , but long after completing therapy. Secondary malignancies belong to serious late complications after HSCT. A significant association of certain risk factors with increased likelihood of secondary malignancies after HSCT has been published over the last ten years. Better knowledge of pathogenesis of these complications, their early identification and treatment may contribute to better health outcomes of allogeneic and autologous hematopoietic stem cell transplantation recipients. We review here the incidence and risk factors of secondary malignancies after hematopoietic stem cell transplantation.
造血干细胞移植（HSCT）为患有恶性和非恶性疾病的患者提供了延长生命的治疗机会。成功进行 HSCT 后的幸存者人数不断增加。然而，HSCT 可导致不仅“在治疗中”而且在完成治疗后很久发生的组织和器官损伤。继发性恶性肿瘤属于 HSCT 后的严重晚期并发症。在过去十年中，已经发表了某些危险因素与 HSCT 后继发性恶性肿瘤发生的可能性增加之间的显著相关性。更好地了解这些并发症的发病机制，及早发现和治疗可能有助于改善异基因和自体造血干细胞移植受者的健康结局。我们在此回顾造血干细胞移植后继发性恶性肿瘤的发生率和危险因素。
